EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Yeming Wang, Hong Wang, Yu Zhang, Anlin Ma, Dong Liu, Xiaoguang Li, Guoru Yang, Min Deng, Shaofang Wang, Yuanyuan Liu, Chuanmiao Liu, Fangqi Ge und 12 weitere

Nature Medicine · 2025

DOI: 10.1038/s41591-024-03419-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nature Medicine, 2025. Verfasst von Yeming Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National…. Hauptthemen laut MEDLINE: Influenza, Human, Antiviral Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suraxavir marboxil (GP681) is an antiviral drug inhibiting the polymerase acidic protein (PA) of RNA polymerase, of influenza. It has shown therapeutic activity against influenza A and B virus infections in preclinical studies. In this multicenter randomized, double-blind, placebo-controlled, phase 3 trial, we aimed to investigate the efficacy and safety of single-dose suraxavir marboxil (40-mg oral dose) in otherwise healthy outpatients aged 5-65 years with uncomplicated influenza unaccompanied by severe issues. From 28 July 2022 to 31 October 2023, 591 outpatients aged 5-65 years with uncomplicated influenza underwent randomization in 46 research centers in China and were randomly assigned in a 2:1 ratio to receive suraxavir marboxil (40 mg) or placebo within 2 days of symptom onset. The primary outcome was time to alleviation of influenza symptoms (TTAS) (from the start of treatment until body temperature returned to 37.2 °C or less and all seven influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) resolved for at least 21.5 h) within 15 days by treatment. The secondary endpoints included virological indicators, system and respiratory symptoms, PA variant mutation and adverse events. The median TTAS was significantly shorter in the group that received suraxavir marboxil compared to the placebo group (42.0 h versus 63.0 h, P = 0.002). Suraxavir marboxil was associated with more rapid decrease in viral load from baseline than placebo by 1 day after administration, with a mean change of -2.2 ± 1.3 compared to -1.3 ± 1.7 log10 copies per ml (P < 0.001) in the placebo group. Adverse events were reported in 28.4% (112 of 395) of suraxavir marboxil recipients and 23.3% (45 of 193) of placebo recipients, most of which were mild or moderate. The incidences of PA variants with the I38T mutation in the H1N1pdm and H3N2 subtypes were 0.7% (1 of 138) and 0.9% (2 of 213), respectively. Low acquired drug resistance was observed. In this trial, timely single-dose suraxavir marboxil was effective in shortening TTAS and reducing the influenza viral load in patients aged 5-65 years with uncomplicated influenza safely. ClinicalTrials.gov registration: NCT05474755 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanAntiviral AgentsHumansAdultAdolescentMaleMiddle AgedFemaleChildDouble-Blind MethodYoung AdultChild, PreschoolAgedViral LoadChinaTreatment Outcome

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Department of Resp…
  • Department of Infectious Disease, Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Infectious Disease, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China.
  • Department of Infectious Disease, China-Japan Friendship Hospital, Beijing, China.
  • Department of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University; Department of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, Center of Respiratory Medici…
  • Department of Infectious Disease, Peking University Third Hospital, Beijing, China.

Zitieren

APA

Wang, Y., Wang, H., Zhang, Y., Ma, A., Liu, D., Li, X., Yang, G., Deng, M., Wang, S., Liu, Y., Liu, C., Ge, F., Wang, S., Yu, Y., Feng, G., Xiao, Z., Li, X., Sun, Y., Chen, X., …, & Cao, B. (2025). Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03419-3

Vancouver

Wang Y, Wang H, Zhang Y, Ma A, Liu D, Li X, et al. Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine. 2025. doi:10.1038/s41591-024-03419-3

BibTeX
@article{Wang2025,
  author = {Wang, Yeming and Wang, Hong and Zhang, Yu and Ma, Anlin and Liu, Dong and Li, Xiaoguang and Yang, Guoru and Deng, Min and Wang, Shaofang and Liu, Yuanyuan and Liu, Chuanmiao and Ge, Fangqi and Wang, Sikui and Yu, Yunsong and Feng, Ganzhu and Xiao, Zuke and Li, Xing and Sun, Yilan and Chen, Xuyan and Cao, Zhaolong and Ding, Yan and Wu, Xiaoping and Wei, Jun and Cao, Bin},
  title = {Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial},
  journal = {Nature Medicine},
  year = {2025},
  doi = {10.1038/s41591-024-03419-3}
}
Kostenlos starten →